Sanofi Expects Moderate 2023 Profit Growth On Dupixent Demand, But Dampened By Aubagio Generics Competition
Sanofi SA (NASDAQ:SNY) forecasts 2023 adjusted earnings per share to grow by a “low single-digit” percentage, not considering an expected negative…